SEARCH

SEARCH BY CITATION

REFERENCES

  • Adusumalli VE, Yang JT, Wong KK, Kucharczyk N, Sofia RD. (1991) Felbamate pharmacokinetics in the rat, rabbit, and dog. Drug Metabolism and Disposal: the Biological Fate of Chemicals 19:11161125.
  • Ali A, Dua Y, Dudek FE. (2006) Effect of semi-chronic carbamazepine treatment on spontaneous seizures in rats with kainate-induced epilepsy: a drug-in-food method of AED administration. Epilepsia 47(Suppl 4) 297.
  • Ashley JJ, Levy G. (1972) Inhibition of diphenylhydantoin elimination by its major metabolite. Res Commun Chem Pathol Pharmacol 4:297306.
  • Atlas SA, Zweier JL, Nebert DW. (1980) Genetic differences in phenytoin pharmacokinetics: in vivo clearance and in vitro metabolism among inbred strains of mice. Dev Pharmacol Ther 1:281304.
  • Bartoszyk GD, Meyerson N, Reimann W, Satzinger G, Von Hodenberg A. (1986) Gabapentin. In MeldrumBS, PorterRJ (Eds) New anticonvulsant drugs, John Libbey, London , pp. 147164.
  • Benedetti MS, Coupez R, Whomsley R, Nicolas JM, Collart P, Baltes E. (2004) Comparative pharmacokinetics and metabolism of levetiracetam, a new anti-epileptic agent, in mouse, rat, rabbit and dog. Xenobiotica 34:281300.
  • Bertram E, Williamson J, Johnson M, Edelbroek P. (2005) Testing drugs for antiepileptic efficacy in a rat model of chronic limbic epilepsy. Epilepsia 46(Suppl. 8):281282.
  • Bethmann K, Brandt C, Löscher W. (2007) Resistance to phenobarbital extends to phenytoin in a rat model of temporal lobe epilepsy. Epilepsia (in press).
  • Bhargava HN. (1995) Drugs that modify opioid tolerance, physical dependence, and abstinence symptoms: preclinical and clinical studies. NIDA Res Monogr 147:5383.
  • Bourgeois BF, Dodson WE, Ferrendelli JA. (1982) Interactions between primidone, carbamazepine, and nicotinamide. Neurology 32:11221126.
  • Brandt C, Gastens AM, Sun MZ, Hausknecht M, Löscher W. (2006) Treatment with valproate after status epilepticus: Effect on neuronal damage, epileptogenesis, and behavioral alterations in rats. Neuropharmacology 51:789804.
  • Brandt C, Volk HA, Löscher W. (2004) Striking differences in individual anticonvulsant response to phenobarbital in rats with spontaneous seizures after status epilepticus. Epilepsia 45:14881497.
  • Browne TR, Leduc B. (2002) Phenytoin and other hydantoins. Chemistry and biotransformation. In LevyRH, MattsonRH, MeldrumBS, PeruccaE (Eds) Antiepileptic drugs. 5th ed.. Lippincott Williams & Wilkins, Philadelphia , pp. 565580.
  • Caccia S, Guiso G, Samanin R, Garattini S. (1980) Species differences in clobazam metabolism and antileptazol effect. J Pharm Pharmacol 32:101103.
  • Caldwell GW, Wu WN, Masucci JA, McKown LA, Gauthier D, Jones WJ, Leo GC, Maryanoff BE. (2005) Metabolism and excretion of the antiepileptic/antimigraine drug, Topiramate in animals and humans. Eur J Drug Metab Pharmacokinet 30:151164.
  • Castel-Branco MM, Figueiredo IV, Falcao AC, Macedo TR, Caramona MM. (2002) Influence of administration vehicles and drug formulations on the pharmacokinetic profile of lamotrigine in rats. Fundamentals Clinical Pharmacology 16:331336.
  • Castel-Branco M, Lebre V, Falcao A, Figueiredo I, Caramona M. (2003) Relationship between plasma and brain levels and the anticonvulsant effect of lamotrigine in rats. Eur J Pharmacol 482:163168.
  • Connelly JF. (1993) Vigabatrin. Annals of Pharmacotherapy 27:197204.
  • Dickinson RG, Harland RC, Ilias AM, Rodgers RM, Kaufman SN, Lynn RK, Gerber N. (1979) Disposition of valproic acid in the rat: dose-dependent metabolism, distribution, enterohepatic recirculation and choleretic effect. J Pharmacol Exp Ther 211:583595.
  • Doheny HC, Ratnaraj N, Whittington MA, Jefferys JG, Patsalos PN. (1999) Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat. Epilepsy Research 34:161168.
  • Eadie MJ. (1999) The use of antiepileptic drugs in clinical practice. In EadieMJ, VajdaFJE (Eds) Antiepileptic drugs. Pharmacology and therapeutics, Springer, Berlin , pp. 589614.
  • Ebert U, Rundfeldt C, Löscher W. (1994) Sex differences in the anticonvulsant efficacy of phenytoin in amygdala-kindled rats. Brain Research 638:4552.
  • Farghali H, Assael BM, Bossi L, Garattini S, Gerna M, Gomeni R, Morselli PL. (1976) Carbamazepine pharmacokinetics in young, adult and pregnant rats. Relation to pharmacological effects. Arch Int Pharmacodyn Ther 220:125139.
  • File SE, Andrews N. (1993) Benzodiazepine withdrawal: behavioural pharmacology and neurochemical changes. Biochem Soc Symp 59:97106.
  • Gabrielsson JL, Weiner DL. (1999) Methodology for pharmacokinetic/pharmacodynamic data analysis. Pharm Sci Technol Today 2:244252.
  • Gerber N, Weller WL, Lynn R, Rangno RE, Sweetman BJ, Bush MT. (1971) Study of dose-dependent metabolism of 5,5-diphenyl-hydantoin in the rat using new methodology for isolation and quantitation of metabolites in vivo and in vitro. J Pharmacol Exp Ther 178:567579.
  • Gibson EL, Barnfield AM, Curzon G. (1996) Dissociation of effects of chronic diazepam treatment and withdrawal on hippocampal dialysate 5-HT and mCPP-induced anxiety in rats. Behavioural Pharmacology 7:185193.
  • Glien M, Brandt C, Potschka H, Löscher W. (2002) Effects of the novel antiepileptic drug levetiracetam on spontaneous recurrent seizures in the rat pilocarpine model of temporal lobe epilepsy. Epilepsia 43:350357.
  • Grabenstatter HL, Clark S, Dudek FE. (2006) Effects of intraperitoneal and oral carbamazepine on spontaneous seizures in rats with kainate-induced epilepsy. Epilepsia 47:(suppl 4): 306.
  • Grabenstatter HL, Ferraro DJ, Williams PA, Chapman PL, Dudek FE. (2005) Use of chronic epilepsy models in antiepileptic drug discovery: the effect of topiramate on spontaneous motor seizures in rats with kainate-induced epilepsy. Epilepsia 46:814.
  • Gram L, Philbert A. (1986) Oxcarbazepine. In MeldrumBS, PorterRJ (Eds) New anticonvulsant drugs, John Libbey, London , pp. 229236.
  • Halonen T, Nissinen J, Pitkänen A. (2001) Chronic elevation of brain GABA levels beginning two days after status epilepticus does not prevent epileptogenesis in rats. Neuropharmacology 40:53650.
  • Hoffman A, Levy G. (1989) Gender differences in the pharmacodynamics of barbiturates in rats. Pharm Res 6:976981.
  • Holck HGO, Kanan MA, Mills LM, Smith EL. (1937) Studies upon the sex-difference in rats in tolerance to certain barbiturates and to nicotine. J Pharmacol Exp Ther 60:323335.
  • Hönack D, Löscher W. (1989) Amygdala-kindling as a model for chronic efficacy studies on antiepileptic drugs: experiments with carbamazepine. Neuropharmacology 28:599610.
  • Hönack D, Löscher W. (1995) Kindling increases the sensitivity of rats to adverse effects of certain antiepileptic drugs. Epilepsia 36:763771.
  • Iven H, Feldbusch E. (1983) Pharmacokinetics of phenobarbital and propylhexedrine after administration of barbexaclone in the mouse. Naunyn Schmiedebergs Arch Pharmacol 324:153159.
  • Kacew S, Festing MF. (1996) Role of rat strain in the differential sensitivity to pharmaceutical agents and naturally occurring substances. J Toxicol Environment Health 47:130.
  • Kato R, Kamataki T. (1982) Cytochrome P-450 as a determinant of sex difference of drug metabolism in the rat. Xenobiotica 12:787800.
  • Kato R, Yamazoe Y. (1992) Sex-specific cytochrome P450 as a cause of sex- and species-related differences in drug toxicity. Toxicology Letters 6465 Spec No: 661-667
  • Leal KW, Rapport RL, Wilensky AJ, Friel PN. (1979) Single-dose pharmacokinetics and anticonvulsant efficacy of primidone in mice. Annals of Neurology 5:470474.
  • Leite JP, Cavalheiro EA. (1995) Effects of conventional antiepileptic drugs in a model of spontaneous recurrent seizures in rats. Epilepsy Research 20:93104.
  • Levy RH, Mattson RH, Meldrum BS, Perucca E. (2002) Antiepileptic drugs. 5th ed. Lippincott Williams & Wilkins, Philadelphia.
  • Lieber CS, DeCarli LM, Sorrell MF. (1989) Experimental methods of ethanol administration. Hepatology 10:501510.
  • Löscher W. (1978) Serum protein binding and pharmacokinetics of valproate in man, dog, rat and mouse. J Pharmacol Exp Ther 204:255261.
  • Löscher W. (1986) Development of tolerance to the anticonvulsant effect of GABAmimetic drugs in genetically epilepsy-prone gerbils. Pharmacol Biochem Behav 24:10071013.
  • Löscher W. (2002) Basic pharmacology of valproate: a review after 35(years of clinical use for the treatment of epilepsy. CNS Drugs 16:66994.
  • Löscher W, Esenwein H. (1978) Pharmacokinetics of sodium valproate in dog and mouse. Arzneimittel-Forsch 28:782787.
  • Löscher W, Hönack D. (1989) Comparison of the anticonvulsant efficacy of primidone and phenobarbital during chronic treatment of amygdala-kindled rats. Eur J Pharmacol 162:309322.
  • Löscher W, Hönack D. (1995) Comparison of anticonvulsant efficacy of valproate during prolonged treatment with one and three daily doses or continuous (“controlled release”) administration in a model of generalized seizures in rats. Epilepsia 36:929937.
  • Löscher W, Potschka H. (2005) Drug resistance in brain diseases and the role of drug efflux transporters. Nature Rev Neurosci 6:591602.
  • Löscher W, Rundfeldt C. (1990) Development of tolerance to clobazam in fully kindled rats: effects of intermittent flumazenil administration. Eur J Pharmacol 180:255271.
  • Löscher W, Schmidt D. (1988) Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Research 2:145181.
  • Löscher W, Schmidt D. (2002) New horizons in the development of antiepileptic drugs. Epilepsy Research 50:316.
  • Löscher W, Schmidt D. (2006a) New horizons in the development of antiepileptic drugs: innovative strategies. Epilepsy Research 69:183272.
  • Löscher W, Schmidt D. (2006b) Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia 47:12531284.
  • Löscher W, Schwark WS. (1985) Development of tolerance to the anticonvulsant effect of diazepam in amygdala-kindled rats. Exp Neurol 90:373384.
  • Löscher W, Nolting B, Fassbender CP. (1990) The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. I. The influence of administration vehicles. Epilepsy Research 7:173181.
  • Löscher W, Fassbender CP, Nolting B. (1991a) The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Research 8:7994.
  • Löscher W, Hönack D, Fassbender CP, Nolting B. (1991b) The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazol seizure models. Epilepsy Research 8:171189.
  • Löscher W, Hönack D, Richter A, Schulz H-U, Schürer M, Düsing M, Brewster ME. (1995) New injectable aqueous carbamazepine solution through complexing with 2-hydroxypropyl-b-cyclodextrin: Tolerability and pharmacokinetics after intravenous injection in comparison to a glycofurol-based formulation. Epilepsia 36:255261.
  • Löscher W, Hönack D, Rundfeldt C. (1998) Antiepileptogenic effects of the novel anticonvulsant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy. J Pharmacol Exp Ther 284:474479.
  • Mattson RH. (2002) Antiepileptic drug monotherapy in adults. In LevyRH, MattsonRH, MeldrumBS, Perucca E (Eds) Antiepileptic drugs. 5th ed.. Lippincott Williams & Wilkins, Philadelphia , pp. 7295.
  • McBride WJ, Li TK. (1998) Animal models of alcoholism: neurobiology of high alcohol-drinking behavior in rodents. Crit Rev Neurobiol 12:339369.
  • Miller AA, Wheatley P, Sawyer DA, Baxter MG, Roth B. (1986) Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: I. Anticonvulsant profile in mice and rats. Epilepsia 27:483489.
  • Muller G, Schaarschmidt K, Stratmann U. (1992) A new device for long-term continuous enteral nutrition of rats by elementary diet via gastrostomy, following extensive oesophageal or lower gastrointestinal surgery. Lab Anim 26:914.
  • Nau H. (1985) Teratogenic valproic acid concentrations: infusion by implanted minipumps vs conventional injection regimen in the mouse. Toxicol Appl Pharmacol 80:243250.
  • Nau H, Zierer R. (1982) Pharmacokinetics of valproic acid and metabolites in mouse plasma and brain following constant-rate application of the drug and its unsaturated metabolite with an osmotic delivery system. Biopharm Drug Dispos 3:317328.
  • Nau H, Finley P, Williams J, Brendel K. (1983) Valproic acid pharmacokinetics in the mouse following controlled-release of pharmacologic and toxic doses via novel implantable and refillable drug reservoirs. Biopharm Drug Dispos 4:173182.
  • Neels HM, Sierens AC, Naelaerts K, Scharpe SL, Hatfield GM, Lambert WE. (2004) Therapeutic drug monitoring of old and newer anti-epileptic drugs. Clin Chem Lab Med 42:12281255.
  • Patsalos PN. (2002) Levetiracetam: chemistry, biotransformation, pharmacokinetics, and drug interactions. In LevyRH, MattsonRH, MeldrumBS, PeruccaE (Eds) Antiepileptic Drugs. 5th ed. Lippincott Williams & Wilkins, Philadelphia , pp. 428432.
  • Perkins L, Peer C, Fleming V. (1999) Pumps/Osmotic - ALZET® system. InMathiowitzE (Ed) Encyclopedia of controlled drug delivery, version 2. John Wiley, New York , pp. 900906.
  • Pitha J, Sklar P, Nye J. (1988) Drug solubilizers to aid pharmacologists: amorphous cyclodextrin derivatives. Life Sci 43:493495.
  • Pitkänen A, Nissinen J, Jolkkonen E, Tuunanen J, Halonen T. (1999) Effects of vigabatrin treatment on status epilepticus- induced neuronal damage and mossy fiber sprouting in the rat hippocampus. Epilepsy Research 33:6785.
  • Radulovic LL, Turck D, Von Hodenberg A, Vollmer KO, McNally WP, DeHart PD, Hanson BJ, Bockbrader HN, Chang T. (1995) Disposition of gabapentin (neurontin) in mice, rats, dogs, and monkeys. Drug Metab Dispos 23:441448.
  • Rundfeldt C, Löscher W. (1992) Development of tolerance to the anticonvulsant effect of vigabatrin in amygdala-kindled rats. European Journal of Pharmacology 213:351366.
  • Rundfeldt C, Löscher W. (1993) Anticonvulsant efficacy and adverse effects of phenytoin during chronic treatment in amygdala-kindled rats. J Pharmacol Exp Ther 266:216223.
  • Schachter SC. (2002) Current evidence indicates that antiepileptic drugs are antiictal, not antiepileptic. Epilepsy Research 50:6770.
  • Skett P. (1988) Biochemical basis of sex differences in drug metabolism. Pharmacol Ther 38:269304.
  • Stables JP, Bertram E, Dudek FE, Holmes G, Mathern G, Pitkänen A, White HS. (2003) Therapy discovery for pharmacoresistant epilepsy and for disease-modifying therapeutics: summary of the NIH/NINDS/AES models II workshop. Epilepsia 44:14721478.
  • Stout SC, Owens MJ, Lindsey KP, Knight DL, Nemeroff CB. (2001) Effects of sodium valproate on corticotropin-releasing factor systems in rat brain. Neuropsychopharmacology 24:624631.
  • Taylor CP, McLean JR, Bockbrader HN, Buchanan RA, Karasawa T, Miyazaki M, Rock DM, Takemoto Y, Uno H, Walker R. (1986) Zonisamide (AD-180, CI-912). In MeldrumBS, PorterRJ (Eds) New anticonvulsant drugs, John Libbey, London , pp. 277296.
  • Temkin NR, Jarell AD, Anderson GD. (2001) Antiepileptogenic agents: how close are we? Drugs 61:104555.
  • Teschendorf H-J, Kretschmar R. (1985) Succinimides. In FreyH-H, JanzD (Eds) Antiepileptic drugs, Springer, Berlin , pp. 557574.
  • Urquhart J. (2000) Internal medicine in the 21st century: controlled drug delivery: therapeutic and pharmacological aspects. Journal of Internal Medicine 248:357376.
  • Van Der Klejin, Van Rossum JM, Muskens ET, Rijntjes NV. (1971) Pharmacokinetics of diazepam in dogs, mice and humans. Acta Pharmacol Toxicol (Copenh) 29 Suppl 3:109127.
  • Van Vliet EA, Van Schaik R, Edelbroek PM, Redeker S, Aronica E, Wadman WJ, Marchi N, Vezzani A, Gorter JA. (2006) Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia 47:672680.
  • Walker MC, Tong X, Perry H, Alavijeh MS, Patsalos PN. (2000) Comparison of serum, cerebrospinal fluid and brain extracellular fluid pharmacokinetics of lamotrigine. Br J Pharmacol 130:242248.
  • Wang X, Ratnaraj N, Patsalos PN. (2004) The pharmacokinetic inter-relationship of tiagabine in blood, cerebrospinal fluid and brain extracellular fluid (frontal cortex and hippocampus). Seizure 13:574581.
  • Welty D, Wang Y, Busch JA, Taylor CP, Vartanian MG, Radulovic LL. (1997) Pharmacokinetics (PK) and pharmacodynamics (PD) of CI-1009 (pregabalin) ans gabapentin in rats with maximal electroshock. Epilepsia 38(Suppl. 8):3536.